Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal onabotulinumtoxinA for accordion cheek wrinkles
ACTRN12614000196640Phase 2Recruiting
- Sponsor
- David Ellis
- Start
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A (2 arms), sponsored by David Ellis. Primary endpoint: Improvement of accordion wrinkles at week 16. Started Feb 2014; status: recruiting.
02
Drugs
botulinum toxin type A
Beyond the preview
Go deeper on ACTRN12614000196640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000196640.